Free Trial

AnaptysBio (ANAB) Competitors

AnaptysBio logo
$26.94 -0.05 (-0.19%)
Closing price 04:00 PM Eastern
Extended Trading
$26.92 -0.02 (-0.07%)
As of 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ANAB vs. KYMR, CRNX, MOR, ALVO, MIRM, CPRX, GMTX, AMRX, NAMS, and RARE

Should you be buying AnaptysBio stock or one of its competitors? The main competitors of AnaptysBio include Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), MorphoSys (MOR), Alvotech (ALVO), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), Gemini Therapeutics (GMTX), AMNEAL PHARMACEUTICALS (AMRX), NewAmsterdam Pharma (NAMS), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry.

AnaptysBio vs. Its Competitors

Kymera Therapeutics (NASDAQ:KYMR) and AnaptysBio (NASDAQ:ANAB) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

In the previous week, AnaptysBio had 3 more articles in the media than Kymera Therapeutics. MarketBeat recorded 6 mentions for AnaptysBio and 3 mentions for Kymera Therapeutics. AnaptysBio's average media sentiment score of 1.10 beat Kymera Therapeutics' score of 1.09 indicating that AnaptysBio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kymera Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AnaptysBio
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Kymera Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of -0.27, meaning that its share price is 127% less volatile than the S&P 500.

Kymera Therapeutics currently has a consensus price target of $59.11, indicating a potential upside of 29.09%. AnaptysBio has a consensus price target of $47.13, indicating a potential upside of 74.93%. Given AnaptysBio's higher possible upside, analysts plainly believe AnaptysBio is more favorable than Kymera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kymera Therapeutics
0 Sell rating(s)
1 Hold rating(s)
17 Buy rating(s)
2 Strong Buy rating(s)
3.05
AnaptysBio
0 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.80

AnaptysBio has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera Therapeutics$47.07M63.35-$223.86M-$3.10-14.77
AnaptysBio$91.28M8.67-$145.23M-$4.85-5.55

AnaptysBio has a net margin of -125.70% compared to Kymera Therapeutics' net margin of -409.07%. Kymera Therapeutics' return on equity of -30.11% beat AnaptysBio's return on equity.

Company Net Margins Return on Equity Return on Assets
Kymera Therapeutics-409.07% -30.11% -25.65%
AnaptysBio -125.70%-282.47%-30.79%

Summary

Kymera Therapeutics beats AnaptysBio on 8 of the 15 factors compared between the two stocks.

Get AnaptysBio News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ANAB vs. The Competition

MetricAnaptysBioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$792.98M$3.07B$5.70B$9.51B
Dividend YieldN/A2.36%4.69%4.01%
P/E Ratio-5.5521.0428.0720.05
Price / Sales8.67284.46448.5799.42
Price / CashN/A42.7636.2258.56
Price / Book11.568.378.665.87
Net Income-$145.23M-$55.19M$3.25B$258.55M
7 Day Performance3.94%5.89%4.20%2.23%
1 Month Performance15.92%17.63%10.82%12.76%
1 Year Performance-27.64%5.09%34.70%19.36%

AnaptysBio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANAB
AnaptysBio
1.7555 of 5 stars
$26.94
-0.2%
$47.13
+74.9%
-26.9%$792.98M$91.28M-5.55100News Coverage
Positive News
Analyst Forecast
KYMR
Kymera Therapeutics
3.0325 of 5 stars
$45.14
-2.3%
$59.11
+31.0%
+6.9%$3.01B$47.07M0.00170Positive News
CRNX
Crinetics Pharmaceuticals
3.6692 of 5 stars
$30.95
-0.5%
$69.50
+124.6%
-43.1%$2.91B$1.04M0.00210Positive News
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
ALVO
Alvotech
2.6708 of 5 stars
$8.64
+0.1%
$16.00
+85.2%
-21.0%$2.60B$491.98M14.881,032
MIRM
Mirum Pharmaceuticals
3.8597 of 5 stars
$51.95
+0.0%
$65.50
+26.1%
+33.5%$2.57B$336.89M0.00140Positive News
CPRX
Catalyst Pharmaceuticals
4.9232 of 5 stars
$21.01
-0.1%
$32.83
+56.3%
+20.0%$2.57B$491.73M13.3880News Coverage
Positive News
Analyst Revision
GMTX
Gemini Therapeutics
N/A$57.77
0.0%
N/A+32.1%$2.50BN/A-57.7730High Trading Volume
AMRX
AMNEAL PHARMACEUTICALS
3.1391 of 5 stars
$7.91
-0.8%
$11.60
+46.6%
+8.0%$2.50B$2.79B13.518,100
NAMS
NewAmsterdam Pharma
3.7871 of 5 stars
$22.56
+1.6%
$41.30
+83.1%
+23.8%$2.49B$45.56M0.004
RARE
Ultragenyx Pharmaceutical
4.3623 of 5 stars
$26.39
+0.3%
$83.64
+216.9%
-39.5%$2.49B$560.23M-4.491,294Upcoming Earnings
Gap Down
High Trading Volume

Related Companies and Tools


This page (NASDAQ:ANAB) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners